RESUMO
This study was conducted to investigate the influence of in ovo vitamin D3 (Vit D3) administration on growth of broiler chickens when Vit D3 was dissolved in soybean oil. Sixty Ross broiler eggs were incubated at 37.8°C and >60% relative humidity. Distilled water, soybean oil, or Vit D3 (60 IU / 0.5 mL) dissolved in soybean oil, was administered in ovo on Day 18 of incubation. Seven days after hatching, chicks were sexed, and 12 birds (six female and six male) close to the average body weight (BW) of each treatment were selected and their BW continuously recorded until 28 days of age, then sacrificed. Liver and pectoral muscle were collected to determine the mRNA expression of IGF-1 and IGF-1 receptor, and the length of tibia was measured. There were no significant differences in BW, liver weight, or pectoral muscle weight between the groups. However, an interaction was observed between treatments and sexes in the tibia length. In comparison among only males, tibia length in the Vit D3 with oil group was longer than that of the control, but not different from that of the oil group. The same tendency was observed in the hepatic IGF-1 mRNA expression in chicks of either sex, with this effect only being observed after the treatments and not in the control. On the other hand, there was an interaction between treatments and sexes in the mRNA expression of IGF-1 receptor, which was highest in the Vit D3 with oil group in females, but not in males. These results indicated that the in ovo administration of Vit D3 affected IGF-1 receptor mRNA expression without growth.
RESUMO
About 50-75% of patients with Henoch-Schönlein purpura (HSP) develop gastro-intestinal symptoms with surgical complications such as intussusception occurring in 0.7-13.6%. In 10-40% of patients, however, gastro-intestinal manifestations may precede the onset of purpura. In patients with gastro-intestinal tract involvement without purpura, confirming the diagnosis of HSP and determining the appropriate treatment remains difficult. A seven-year-old boy presented with recurrent intussusception owing to HSP without purpura. It was confirmed pathologically and treated via colonoscopy. Early colonoscopic intervention can contribute to the early diagnosis of HSP and its subsequent management by avoiding unnecessary surgical invasion.
Assuntos
Colonoscopia/métodos , Vasculite por IgA/complicações , Vasculite por IgA/diagnóstico , Intussuscepção/diagnóstico , Intussuscepção/prevenção & controle , Criança , Humanos , Masculino , Prevenção SecundáriaRESUMO
A 79-year-old man was admitted because of cholecystitis that occurred about 40 days after sigmoidectomy had been performed for colonic cancer. Though antibiotics improved his condition, the patient had hematochezia, diarrhea, and left lower abdominal pain. Colonoscopic findings showed multiple ring-like areas of redness and petechiae in the rectosigmoid colon and marked edema from the descending to the transverse colon. The patient then developed purpura on the extensor surfaces of the legs and bilateral gonalgia, and exacerbation of the hematochezia. A second colonoscopy (CS) showed multiple ring-like areas of redness and ecchymosis throughout the colon. The patient was diagnosed with Henoch-Schönlein purpura (HSP), and the symptoms were attenuated after the administration of prednisolone. However, diarrhea recurred in about a week; stool culture confirmed Clostridium difficile, and a third CS revealed pseudomembranes throughout the colon. The patient was diagnosed with pseudomembranous colitis (PMC), and the administration of vancomycin attenuated the symptoms. In conclusion, we have reported a rare adult case of PMC that occurred during prednisolone treatment for HSP. The PMC may have been caused by changes in the intestinal bacterial flora after the sigmoidectomy and by the intestinal lesions of HSP, as well as by the administration of antibiotics after the sigmoidectomy and for the treatment of cholecystitis, and by the use of prednisolone for the treatment of the HSP.
Assuntos
Clostridioides difficile/isolamento & purificação , Enterocolite Pseudomembranosa/etiologia , Vasculite por IgA/complicações , Idoso , Antibacterianos/uso terapêutico , Biópsia , Colo/microbiologia , Colo/patologia , Colonoscopia , Enterocolite Pseudomembranosa/tratamento farmacológico , Enterocolite Pseudomembranosa/patologia , Seguimentos , Glucocorticoides/efeitos adversos , Glucocorticoides/uso terapêutico , Humanos , Vasculite por IgA/tratamento farmacológico , Masculino , Prednisolona/efeitos adversos , Prednisolona/uso terapêutico , Vancomicina/uso terapêuticoRESUMO
The principal objective of this experiment was to evaluate the effect of 25-hydroxy-cholecalciferol (25-OH-D3 ) on the development of osteochondrosis in 6- to 110-kg castrated male pigs. The growth rate and serum calcium and inorganic phosphate levels neither increased nor decreased in response to supplementation of 25-OH-D3 . However, supplemental 25-OH-D3 significantly increased serum levels of 25-OH-D3 and 1α,25-hydroxy-cholecalciferol without any influence on bone mineral density. The 25-OH-D3 -treated group had significant (P < 0.05) reduced incidence of osteochondrotic lesions compared to the control group as evidenced by macroscopically examining the articular cartilage of the distal humerus (32.4% vs. 59.3%) and distal femur (47.1% vs. 87.5%). Likewise, supplemental 25-OH-D3 significantly reduced osteochondrotic lesions over the control when histologically examining humerus (20.6% vs. 43.8%) and femur (52.9% vs. 87.5%). The results of this experiment suggested that 25-OH-D3 supplementation in pig diets had a tendency to promote normal endochondral ossification, inhibit osteochondrosis progression and possibly regenerate destroyed cartilage tissue.
Assuntos
Calcifediol/farmacologia , Osteocondrose/veterinária , Doenças dos Suínos/prevenção & controle , Animais , Biomarcadores/sangue , Densidade Óssea , Osso e Ossos/química , Osso e Ossos/patologia , Calcifediol/sangue , Cálcio/sangue , Masculino , Osteocondrose/patologia , Osteocondrose/prevenção & controle , Osteogênese/efeitos dos fármacos , Fosfatos/sangue , SuínosRESUMO
Imidazole-related dipeptides, such as carnosine and anserine, occur widely in skeletal muscles of jawed vertebrates. All of the known enzymes that catalyze the hydrolysis of these dipeptides belong to the M20A metallopeptidase subfamily; two secretory enzymes, serum carnosinase (EC 3.4.13.20) and anserinase (EC 3.4.13.5), and one non-secretory enzyme, cytosolic nonspecific dipeptidase (EC 3.4.13.18). Here we report the enzymatic characterization and molecular identification of an unidentified enzyme, which catalyzes the hydrolysis of these dipeptides, from the skeletal muscle of Far Eastern brook lamprey (Lethenteron reissneri). A 60-kDa subunit protein of the enzyme was purified to near homogeneity. We cloned two M20A genes from the skeletal muscle of Far Eastern brook lamprey; one was a secretory-type gene encoding for the 60-kD protein, and another was a non-secretory-type gene presumably encoding for cytosolic nonspecific dipeptidase. Our findings indicate that the purified enzyme is a N-glycosylated secretory M20A dipeptidase distributed specifically in the jawless vertebrate group, and may be derived from a common ancestor gene between serum carnosinase and anserinase. We propose that this dipeptidase is a novel secretory M20A enzyme and is classified as neither serum carnosinase nor anserinase.